2021 Year in Review: On Why We Do What We Do

2021 Year in Review

Despite the persistent challenges presented by the ongoing pandemic, our teams delivered critical assays and reagents, scaled production of our COVID-19 offerings, expanded our team, services, and facilities, and supported scientists and healthcare providers across the world.

[Read More…]

Developing a New Multiplex Assay for Early Detection of Colorectal Cancer

Early detection makes a real difference in outcomes for cancer patients. But for cases of colorectal cancer, detecting tumors in the earliest stages has been virtually impossible. The team at EDP Biotech is committed to changing that by developing a simple, accurate, blood-based diagnostic test for biomarkers of colorectal cancer.

[Read More…]

Luminex Licensed Technologies Partner Spotlight: Wageningen Prime Diagnostics

Scientists at Wageningen Prime Diagnostics often design multiplex assays to allow customers to test for many pathogens at once. They use Luminex’s bead-based multiplexing xMAP® Technology for streamlined development, reliable components, and robust test kits. Prime Diagnostics has been a Luminex Licensed Technologies Partner since 2007 and now offers more than 100 xMAP-based kits for pathogen detection in plants.

[Read More…]